Lincoln Pharma reports 22.8 percent rise in standalone net profit at Rs. 21.6 crore in Q3 FY23
Ahmedabad: Lincoln Pharmaceuticals Ltd has reported net profit of Rs. 21.61 crore for the Q3 FY23 ended December 2022 as against net profit of Rs. 17.60 crore in the corresponding period last year, growth of 22.8%.
Total Income for the Q3 FY23 was reported at Rs. 140.12 crore, higher by 14.4% over previous fiscal’s same period Total Income of Rs. 122.5 crore. The company reported EBITDA of Rs. 33.1 crore in Q3 FY23, rise of 26.9% as compared to Rs. 26.1 crore in the corresponding period last year. EPS for Q3FY23 was at Rs. 10.79 per share for as compared to Rs. 8.79 in the corresponding period last year.
During the year, company got an approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products at Cephalosporin plant. The production from this plant will be expected to generate from this year last quarter.
Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “Company has delivered a robust operational and financial performance during the quarter and confident to improve our growth numbers going forward. Recently company has also received an approval from Australia's medicines and medical devices regulator - Therapeutic Goods Administration (TGA) for its Khatraj facility. TGA and EU GMP approvals will further strengthen company's presence in the export market. Strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximize value for all stakeholders in the near to medium term.
Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents.
Read also: Lincoln Pharma reports over 30 percent rise in net profit in Q3
